Therapeutic Peptide Development Platforms
Peptides have a higher development success rate than small molecules and are widely used in the treatment of various diseases. Our company's therapeutic peptide development platforms provide customers with a high-quality and flexible solution. With years of accumulated experience through cooperation projects and the perfect platform and technical capabilities, our team can customize experimental designs for your rare disease project according to your specific requirements.
Overview of Therapeutic Peptides
The molecular weight of therapeutic peptide is usually 500 ~ 5000 Da1. The peptide is a compound formed by connecting α-amino acids with peptide bonds. It is also an intermediate product of protein hydrolysis. Initially, scientists studied and isolated bioactive peptides from natural substances. In the 1920s, insulin, a 51-amino acid peptide, was discovered and used to treat diabetes.
With the advancement of analytical technology and scientific research capabilities, more and more therapeutic peptides have been developed into therapeutic drugs, from an initial length of less than 10 amino acids to an average length of 40 amino acids.
Therapeutic Peptides for Rare Disease
Therapeutic peptides have the characteristics of low production cost, high specificity, and low toxicity. With the development of various peptide modification technologies, the peptides' limitations have been overcome, and the uniqueness of therapeutic peptides has been further developed. Therefore, therapeutic peptides play an increasingly important role in researching and developing rare disease therapies. There are already some examples of therapeutic peptides being used in rare disease treatment and research:
- Pramlintide for Diabetes Mellitus
- Carfilzomib for Multiple Myeloma
- Taltirelin for Spinocerebellar Degeneration
- Pasireotide for Cushing Disease
Modified peptides are widely used in rare disease therapy research. Our company provides peptide modification services, as well as peptide analysis using chromatography and mass spectrometry to ensure its quality.
Our company uses different synthesis methods such as head-to-tail, head-to-side-chain, side-chain-to-side-chain, and side-chain-to-tail to provide you with the synthesis of cyclopeptides for your rare disease therapy research project.
Our company provides microwave, solid phase peptide synthesis (SPPS), and liquid phase peptide synthesis (LPPS) technology to support neoantigen peptides development to meet your various needs in rare disease research.
Long-chain peptides are comparable in size to the mean protein domain. Our company provides peptide synthesis, peptide Isolation and peptide analysis to improve the efficiency of rare disease research.
As a CRO with multi-platform capabilities, our company provides peptidomimetic library screening, peptidomimetic synthesis and analysis to speed up your rare disease research process.
With a research team with extensive expertise in rare disease therapy research and development, our company is confident in providing customers with therapeutic peptide development. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Wang, Lei, et al. "Therapeutic peptides: Current applications and future directions." Signal Transduction and Targeted Therapy 7.1 (2022): 48.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.